Program
Ezetimibe
Also written as “ezetimibe”, “ezetimibe (+) simvastatin” and “MK0653, ezetimibe”.
Its studies are mostly in Hypercholesterolemia · Hypertension · Hyperlipidemias · Lipid Metabolism, Inborn Errors · Atherosclerosis, led by 16 companies.
Drug pageEzetimibe: every studyMany companies study it; this page follows only the 97 they lead. All 208 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organon | 710 open or running | phase 4since Sep 7, 2005 | Sep 23, 2004 | none ahead |
| Daiichi Sankyoits history only | 61 open or running | phase 4since Sep 9, 2005 | Sep 9, 2005 | Jun 1, 2028phase 3 · NCT07474649 |
| Yuhanits history only | 40 open or running | phase 4since Jul 12, 2017 | Jul 12, 2017 | none ahead |
| IlDong Pharmaceuticalits history only | 20 open or running | phase 3since Sep 25, 2014 | Sep 25, 2014 | none ahead |
| JW Pharmaceuticalits history only | 21 open or running | phase 4since Feb 18, 2026 | Oct 6, 2020 | none ahead |
| Novartisits history only | 20 open or running | phase 4since Oct 10, 2006 | Sep 12, 2005 | none ahead |
| Celltrionits history only | 10 open or running | phase 3since Apr 27, 2026 | Apr 27, 2026 | none ahead |
| Daewon Pharmaceuticalits history only | 10 open or running | phase 3since Jul 24, 2023 | Jul 24, 2023 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Mar 22, 2012 | Mar 22, 2012 | none ahead |
| Hanlim Pharm.its history only | 10 open or running | phase 3since Dec 2, 2020 | Dec 2, 2020 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 1since Apr 29, 2014 | Apr 29, 2014 | none ahead |
| HK inno.Nits history only | 10 open or running | phase 4since Nov 20, 2018 | Nov 20, 2018 | none ahead |
| Hyundai Pharmits history only | 11 open or running | phase 3since Oct 15, 2024 | Oct 15, 2024 | none ahead |
| Merckits history only | 10 open or running | phase 4since Sep 16, 2008 | Sep 16, 2008 | none ahead |
| NVP Healthcareits history only | 10 open or running | phase 1since Nov 9, 2014 | Nov 9, 2014 | none ahead |
| Shin Poong Pharmaceuticalits history only | 10 open or running | phase 3since Aug 18, 2017 | Aug 18, 2017 | none ahead |
Also a collaborator on its studies: Pharma Medica Research, Regeneron Pharmaceuticals, Merck Frosst Canada, Linical Korea and Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Organon only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 24 studies since Aug 9, 2005.
- Mar 31, 20086 phase 4 studiesNCT00652444, NCT00652327, NCT00651963 and 3 more
- Mar 31, 20086 phase 3 studiesNCT00652301, NCT00651560, NCT00651404 and 3 more
- Apr 1, 20082 phase 3 studies in HypercholesterolemiaNCT00654095, NCT00653523
- Apr 1, 20085 phase 4 studiesNCT00653835, NCT00653796, NCT00652847 and 2 more
- Apr 1, 2008Phase 1 study in CholesterolNCT00653276 · 13 enrolled
- Mar 12, 20092 phase 3 studiesNCT00862251, NCT00867165
- Mar 26, 2009Phase 4 study in Primary HypercholesterolemiaNCT00871351 · 125 enrolled
- Jun 29, 2010Phase 3 study in HypercholesterolemiaNCT01154036 · 1,547 enrolled
- Jun 8, 20112 phase 3 studies in HypercholesterolemiaNCT01370603, NCT01370590
- Jun 1, 2012Phase 4 study in HypercholesterolemiaNCT01611883 · 152 enrolled
- May 29, 2015Phase 3 study in HypercholesterolemiaNCT02460159 · 135 enrolled
- Sep 14, 2015Phase 3 study in HypercholesterolemiaNCT02550288 · 309 enrolled
- Apr 13, 20162 phase 3 studies in HypercholesterolemiaNCT02741245, NCT02748057
- Mar 6, 20195 phase 3 studiesNCT03884452, NCT03867110, NCT03882996 and 2 more
TargetBeta
“Niemann-Pick C1-like protein 1 inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 71 Organon leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03882996Hypercholesterolemia | 3 | Completed | Feb 4, 2003 | 432 |
| NCT03882905Primary Hypercholesterolemia | 3 | Completed | Jul 27, 2001 | 769 |
| NCT03882892Hypercholesterolemia | 3 | Completed | Aug 8, 2002 | 400 |
| NCT03884452Hyperlipoproteinemia Type II | 3 | Completed | May 24, 2001 | 50 |
| NCT03867110Hypercholesterolemia | 3 | Completed | Jul 27, 2001 | 628 |
| NCT02748057Hypercholesterolemia | 3 | Completed | Dec 11, 2017 | 135 |
| NCT02741245Hypercholesterolemia | 3 | Completed | Jan 18, 2017 | 321 |
| NCT02550288Hypercholesterolemia | 3 | Completed | May 30, 2016 | 309 |
| NCT02460159Hypercholesterolemia | 3 | Completed | Dec 22, 2016 | 135 |
| NCT01611883Hypercholesterolemia | 4 | Completed | Jan 16, 2014 | 152 |
| NCT01370603Hypercholesterolemia | 3 | Completed | May 2012 | 328 |
| NCT01370590Hypercholesterolemia | 3 | Completed | Apr 2012 | 406 |
| NCT01154036Hypercholesterolemia | 3 | Completed | Sep 2012 | 1,547 |
| NCT00871351Primary Hypercholesterolemia | 4 | Completed | May 1, 2010 | 125 |
| NCT00867165Primary Hypercholesterolemia | 3 | Completed | Apr 13, 2012 | 138 |
| NCT00862251Cardiovascular Diseases | 3 | Completed | Mar 2011 | 808 |
| NCT00654628Hypercholesterolemia | 4 | Completed | Jul 1, 2009 | 173 |
| NCT00654095Hypercholesterolemia | 3 | Completed | Jun 1, 2009 | 146 |
| NCT00653835Hypercholesterolemia | 4 | Completed | Aug 1, 2004 | 153 |
| NCT00653796Hypercholesterolemia | 4 | Completed | Aug 1, 2004 | 148 |
| NCT00653523Hypercholesterolemia | 3 | Completed | Jun 1, 2009 | 151 |
| NCT00653276Cholesterol | 1 | Completed | Jan 2004 | 13 |
| NCT00652847Hypercholesterolemia | 4 | Completed | May 2007 | 1,140 |
| NCT00652717Cardiovascular Diseases | 4 | Completed | Feb 15, 2005 | 280 |
| NCT00653913Hypercholesterolemia | 1 | Completed | Sep 2004 | 18 |
| NCT00652444Hypercholesterolemia | 4 | Completed | Aug 2004 | 120 |
| NCT00652327Hypercholesterolemia | 4 | Completed | Jul 2007 | 83 |
| NCT00652301Cholesterol | 3 | Completed | Apr 2004 | 40 |
| NCT00651963Lipid Metabolism Disorders | 4 | Completed | Mar 2005 | 80 |
| NCT00651560Hyperlipidemias | 3 | Completed | Dec 23, 2005 | 167 |
| NCT00651404Hypercholesterolemia | 3 | Completed | Dec 2004 | 137 |
| NCT00651391Hypercholesterolemia | 3 | Terminated | Sep 1, 2004 | 28 |
| NCT00651274Atherosclerosis | 4 | Completed | Aug 1, 2004 | 144 |
| NCT00651144Hypercholesterolemia | 1 | Completed | May 2003 | 40 |
| NCT00651014Hypercholesterolemia | 4 | Terminated | Jun 2006 | 82 |
| NCT00650819Hypercholesterolemia | 3 | Completed | Feb 1, 2005 | 240 |
| NCT00650689Hypercholesterolemia | 3 | Completed | Dec 2004 | 122 |
| NCT00650663Hypercholesterolemia | 4 | Completed | Sep 1, 2004 | 247 |
| NCT00552097Atherosclerosis | 3 | Completed | Apr 25, 2006 | 720 |
| NCT00535405Hypercholesterolemia | 3 | Completed | Mar 2009 | 1,289 |
| NCT00496730Hypercholesterolemia | 3 | Completed | Aug 2008 | 256 |
| NCT00479713Hypercholesterolemia | 3 | Completed | Mar 1, 2008 | 618 |
| NCT00462748Hypercholesterolemia | 3 | Completed | Jun 2008 | 786 |
| NCT00457275Hypercholesterolemia | 3 | Completed | Nov 2005 | 440 |
| NCT00442897Hypercholesterolemia | 4 | Completed | Oct 2008 | 229 |
| NCT00423579Hypercholesterolemia | 4 | Completed | Mar 1, 2008 | 120 |
| NCT00423488Hypercholesterolemia | 3 | Completed | Feb 16, 2007 | 93 |
| NCT00418834Hypercholesterolemia | 3 | Completed | Oct 2008 | 1,053 |
| NCT00413972Hypercholesterolemia | 3 | Completed | Nov 2006 | 392 |
| NCT00409773Hypercholesterolemia | 3 | Completed | Jul 2008 | 1,143 |
| NCT00395473Hypercholesterolemia | 3 | Completed | Nov 2005 | 141 |
| NCT00319449Hypercholesterolemia | 4 | Completed | Oct 2006 | 22 |
| NCT00276484Hypercholesterolemia | 3 | Completed | Feb 2008 | 579 |
| NCT00276458Hypercholesterolemia | 3 | Completed | Jan 2008 | 196 |
| NCT00271817Hypercholesterolemia | 3 | Completed | Feb 2008 | 1,220 |
| NCT00202904Hypercholesterolemia | 4 | Completed | Oct 2006 | 81 |
| NCT00166530Atherosclerosis | 4 | Completed | Feb 2007 | 367 |
| NCT00166504Hypercholesterolemia | 4 | Completed | Oct 2007 | 203 |
| NCT00157924Hypercholesterolemia | 4 | Completed | Sep 2007 | 190 |
| NCT00129402Hypercholesterolemia | 3 | Completed | Jun 2007 | 248 |
How it is read
Names in the registry
- “Ezetimibe”, 31 entries
- “ezetimibe”, 11 entries
- “ezetimibe (+) simvastatin”, 10 entries
- “MK0653, ezetimibe”, 7 entries
- “CKD-828, D097, D337”, 6 entries
Codes read as this program: MK0653.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 73 studies
- Hypertension, 9 studies
- Hyperlipidemias, 7 studies
- Lipid Metabolism, Inborn Errors, 3 studies
- Atherosclerosis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.